182 related articles for article (PubMed ID: 9168001)
1. Sex steroid hormones, bone mineral density, and risk of breast cancer.
Kuller LH; Cauley JA; Lucas L; Cummings S; Browner WS
Environ Health Perspect; 1997 Apr; 105 Suppl 3(Suppl 3):593-9. PubMed ID: 9168001
[TBL] [Abstract][Full Text] [Related]
2. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
[TBL] [Abstract][Full Text] [Related]
3. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.
Colditz GA
J Natl Cancer Inst; 1998 Jun; 90(11):814-23. PubMed ID: 9625169
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group.
Cauley JA; Lucas FL; Kuller LH; Vogt MT; Browner WS; Cummings SR
JAMA; 1996 Nov; 276(17):1404-8. PubMed ID: 8892715
[TBL] [Abstract][Full Text] [Related]
5. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates.
Beckmann MW; Jap D; Djahansouzi S; Nestle-Krämling C; Kuschel B; Dall P; Brumm C; Bender HG
Oncology; 2001; 60(3):199-206. PubMed ID: 11340370
[TBL] [Abstract][Full Text] [Related]
7. Axial BMD, change in BMD and bone turnover do not predict breast cancer incidence in early postmenopausal women.
Stewart A; Kumar V; Torgerson DJ; Fraser WD; Gilbert FJ; Reid DM
Osteoporos Int; 2005 Dec; 16(12):1627-32. PubMed ID: 15782281
[TBL] [Abstract][Full Text] [Related]
8. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
Khoo SK; Chick P
Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors.
Cauley JA; Song J; Dowsett SA; Mershon JL; Cummings SR
Breast Cancer Res Treat; 2007 Apr; 102(2):181-8. PubMed ID: 17028986
[TBL] [Abstract][Full Text] [Related]
10. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
12. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
[TBL] [Abstract][Full Text] [Related]
13. Additive effects of weight-bearing exercise and estrogen on bone mineral density in older women.
Kohrt WM; Snead DB; Slatopolsky E; Birge SJ
J Bone Miner Res; 1995 Sep; 10(9):1303-11. PubMed ID: 7502701
[TBL] [Abstract][Full Text] [Related]
14. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of Osteoporotic Fractures Research Group.
Lucas FL; Cauley JA; Stone RA; Cummings SR; Vogt MT; Weissfeld JL; Kuller LH
Am J Epidemiol; 1998 Jul; 148(1):22-9. PubMed ID: 9663400
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
Trémollieres FA; Pouilles JM; Ribot C
Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
[TBL] [Abstract][Full Text] [Related]
17. Factors of risk for breast cancer influencing post-menopausal long-term hormone replacement therapy.
Chiechi LM; Secreto G
Tumori; 2000; 86(1):12-6. PubMed ID: 10778760
[TBL] [Abstract][Full Text] [Related]
18. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
19. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
[TBL] [Abstract][Full Text] [Related]
20. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy.
Milliken LA; Going SB; Houtkooper LB; Flint-Wagner HG; Figueroa A; Metcalfe LL; Blew RM; Sharp SC; Lohman TG
Calcif Tissue Int; 2003 Apr; 72(4):478-84. PubMed ID: 12574871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
